Skip to main content
Top
Published in: Journal of General Internal Medicine 6/2008

01-06-2008 | Case Reports/Clinical Vignettes

Cushing’s Syndrome Due to Ectopic Adrenocorticotropic Hormone Production Secondary to Hepatic Carcinoid: Diagnosis, Treatment, and Improved Quality of Life

Authors: Susan G. Coe, MD, Winston W. Tan, MD, Thomas P. Fox, MD

Published in: Journal of General Internal Medicine | Issue 6/2008

Login to get access

Abstract

INTRODUCTION

We describe a previously healthy 40-year-old woman with Cushing’s syndrome caused by adrenocorticotropic hormone (ACTH) secretion from metastatic carcinoid.

CASE REPORT

Over a 2-year period, the patient had multiple hospitalizations for uncontrolled hypertension, hyperglycemia, and hypokalemia. She had transient flushing, rashes, and a rapid weight gain. In addition, she developed anasarca and had a nontraumatic hip fracture 1 month before presentation. Subsequently, a hypertensive crisis resulted in admission to the intensive care unit and fine-needle aspiration of a liver lesion.

DISCUSSION

A diagnosis of metastatic carcinoid was established. She was transferred to our hospital for further evaluation and management. On arrival, she had the signs of Cushing’s syndrome. Despite extensive evaluation, her primary carcinoid tumor was not localized. She was treated successfully with bilateral adrenalectomy and octreotide.

CONCLUSION

This case illustrates how early recognition of the signs and symptoms of excess ACTH is important for prompt and appropriate treatment.
Literature
1.
go back to reference Nieman LK, Ilias I. Evaluation and treatment of Cushing’s syndrome. Am J Med. 2005;118(12):1340–6.PubMedCrossRef Nieman LK, Ilias I. Evaluation and treatment of Cushing’s syndrome. Am J Med. 2005;118(12):1340–6.PubMedCrossRef
2.
go back to reference Ross EJ, Linch DC Cushing’s syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet. 1982;2(8299):646–9.PubMedCrossRef Ross EJ, Linch DC Cushing’s syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet. 1982;2(8299):646–9.PubMedCrossRef
3.
go back to reference Ilias I, et al. Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of Health. J Clin Endocrinol Metab. 2005;90(8):4955–62.PubMedCrossRef Ilias I, et al. Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of Health. J Clin Endocrinol Metab. 2005;90(8):4955–62.PubMedCrossRef
4.
go back to reference Whitworth JA, et al. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag. 2005;1(4):291–9.PubMedCrossRef Whitworth JA, et al. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag. 2005;1(4):291–9.PubMedCrossRef
5.
go back to reference Arnaldi G, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88(12):5593–602.PubMedCrossRef Arnaldi G, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88(12):5593–602.PubMedCrossRef
6.
go back to reference Kirk LF Jr, et al. Cushing’s disease: clinical manifestations and diagnostic evaluation. Am Fam Phys. 1133;62(5):1119–27. Kirk LF Jr, et al. Cushing’s disease: clinical manifestations and diagnostic evaluation. Am Fam Phys. 1133;62(5):1119–27.
8.
go back to reference Lindsay JR, Nieman LK. Differential diagnosis and imaging in Cushing’s syndrome. Endocrinol Metab Clin North Am. 2005;34(2):403–21.PubMedCrossRef Lindsay JR, Nieman LK. Differential diagnosis and imaging in Cushing’s syndrome. Endocrinol Metab Clin North Am. 2005;34(2):403–21.PubMedCrossRef
9.
go back to reference Robertson RG, Geiger WJ, Davis NB. Carcinoid tumors. Am Fam Phys. 2006;74(3)429–34. Robertson RG, Geiger WJ, Davis NB. Carcinoid tumors. Am Fam Phys. 2006;74(3)429–34.
10.
go back to reference Torpy DJ, et al. Association of hypertension and hypokalemia with Cushing’s syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci. 2002;970:134–44.PubMedCrossRef Torpy DJ, et al. Association of hypertension and hypokalemia with Cushing’s syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci. 2002;970:134–44.PubMedCrossRef
11.
go back to reference Anthony T, Kim L. Gastrointestinal carcinoid tumors and the carcinoid syndrome, 7th ed. In: Feldman M, Friedman LS, Sleisenger M, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Diseases: Pathophysiology, Diagnosis, Management, Vol. 2. Philadelphia: Saunders; 2002:2151–68. Anthony T, Kim L. Gastrointestinal carcinoid tumors and the carcinoid syndrome, 7th ed. In: Feldman M, Friedman LS, Sleisenger M, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Diseases: Pathophysiology, Diagnosis, Management, Vol. 2. Philadelphia: Saunders; 2002:2151–68.
12.
go back to reference Isidori AM, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab. 2006;91(2):371–7.PubMedCrossRef Isidori AM, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab. 2006;91(2):371–7.PubMedCrossRef
13.
go back to reference Aniszewski JP, et al. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. World J Surg. 2001;25(7):934–40.PubMedCrossRef Aniszewski JP, et al. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. World J Surg. 2001;25(7):934–40.PubMedCrossRef
14.
go back to reference Shah NA, et al. Primary hepatic carcinoid tumor presenting as Cushing’s syndrome. J Endocrinol Invest. 2007;30(4):327–33.PubMed Shah NA, et al. Primary hepatic carcinoid tumor presenting as Cushing’s syndrome. J Endocrinol Invest. 2007;30(4):327–33.PubMed
15.
go back to reference Woltering EA, et al. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas. 2005;31(4):392–400.PubMedCrossRef Woltering EA, et al. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas. 2005;31(4):392–400.PubMedCrossRef
16.
go back to reference Sarmiento JM, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37.PubMedCrossRef Sarmiento JM, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37.PubMedCrossRef
17.
go back to reference Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003;12(1):231–42.PubMedCrossRef Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003;12(1):231–42.PubMedCrossRef
18.
go back to reference Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg. 2001;25(6):693–6.PubMedCrossRef Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg. 2001;25(6):693–6.PubMedCrossRef
19.
go back to reference Mishra AK, et al. Outcome of adrenalectomy for Cushing’s syndrome: experience from a tertiary care center. World J Surg. 2007;31(7):1425–32.PubMedCrossRef Mishra AK, et al. Outcome of adrenalectomy for Cushing’s syndrome: experience from a tertiary care center. World J Surg. 2007;31(7):1425–32.PubMedCrossRef
20.
go back to reference O’Riordain DS, et al. Long-term outcome of bilateral adrenalectomy in patients with Cushing’s syndrome. Surgery. 1994;116(6):1088–93. discussion 1093–4.PubMed O’Riordain DS, et al. Long-term outcome of bilateral adrenalectomy in patients with Cushing’s syndrome. Surgery. 1994;116(6):1088–93. discussion 1093–4.PubMed
Metadata
Title
Cushing’s Syndrome Due to Ectopic Adrenocorticotropic Hormone Production Secondary to Hepatic Carcinoid: Diagnosis, Treatment, and Improved Quality of Life
Authors
Susan G. Coe, MD
Winston W. Tan, MD
Thomas P. Fox, MD
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 6/2008
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-008-0587-z

Other articles of this Issue 6/2008

Journal of General Internal Medicine 6/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine